Treating Together

An interview with Benny Weskler, MBA, MD, FACS, FACCP of Allegheny Health Network.

Federico Albrecht, MD discusses 2 small cell lung cancer cases.

Craig Horbinski, MD, PhD, unpacks the NCCN Clinical Practice Guidelines for central nervous system tumors.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD of Massachusetts General Hospital discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

An interview with Ruchi Garg, MD of City of Hope.

An interview with Warren Swegal, MD.

An interview with Alice P. Chen, MD of the National Cancer Institute.

Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the present and future of prostate cancer precision medicine.

A talk with Sara A. Hurvitz, MD about advances in the HER2-positive breast cancer space.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, of Dana-Farber Cancer Institute discuses new studies in gastrointestinal malignancies.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD of Cancer Treatment Centers of America Atlanta, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD of Cancer Treatment Centers of America, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, Chris Fine, MD, FACC, cardiologist at National Jewish Health, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

In season 3, episode 7 of Targeted Talks, John Nakayama, MD, a gynecologic oncologist at Allegheny Health Network, discusses updates in the endometrial cancer treatment landscape.

Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the latest advances in the treatment of diffuse large B-cell lymphoma.

In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guidelines for managing early-stage breast cancer.

Mark Agulnik, MD, City of Hope Comprehensive Cancer Center joins Targeted Oncology for a discussion about the sarcoma treatment landscape and pending innovations under investigation in clinical trials.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Sandra P. D'Angelo, MD and Katherine Poruk, MD